Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
Hematology Am Soc Hematol Educ Program. 2011;2011:238-42. doi: 10.1182/asheducation-2011.1.238.
Survival rates for children with acute lymphoblastic leukemia (ALL) have increased dramatically over the past 4 decades, with 5-year survival rates of > 90% in recent trials. With the increasing number of children and adolescents cured of ALL, identifying and characterizing the occurrence of long-term adverse late effects has become increasingly important. In this young population, successful treatment of ALL is associated with increased risk of adverse outcomes such as late mortality, second neoplasms, chronic health conditions, endocrine dysfunction, and psychological function. Research efforts conducted through large survivor cohorts, such as the Childhood Cancer Survivor Study, are providing new and important insights into the very long-term consequences of ALL therapy, while providing direction for screening recommendations and intervention-based approaches for reducing late morbidity and mortality.
在过去的 40 年中，急性淋巴细胞白血病 (ALL) 患儿的生存率显著提高，最近的试验中 5 年生存率超过 90%。随着越来越多的儿童和青少年 ALL 被治愈，识别和描述长期不良的晚期影响变得越来越重要。在这一年轻人群中，ALL 的成功治疗与不良后果的风险增加相关，如晚期死亡率、第二肿瘤、慢性健康状况、内分泌功能障碍和心理功能障碍。通过大型幸存者队列（如儿童癌症幸存者研究）进行的研究工作，为 ALL 治疗的长期后果提供了新的重要见解，同时为减少晚期发病率和死亡率的筛查建议和基于干预的方法提供了方向。
